Bristol-Myers Squibb Revenue 2006-2018 | BMY

Current and historical revenue for Bristol-Myers Squibb (BMY) from 2006 to 2018. Revenue can be defined as the sum of all revenue fields included for a company's operating activities. Bristol-Myers Squibb revenue for the twelve months ending June 30, 2018 was $21.600B. Bristol-Myers Squibb revenue for the three months ending June 30, 2018 was $5.704B, representing a 10.89% increase from the same quarter last year.
Bristol-Myers Squibb Annual Revenue
(Millions of US $)
2017 $20,776
2016 $19,427
2015 $16,560
2014 $15,879
2013 $16,385
2012 $17,621
2011 $21,244
2010 $19,484
2009 $18,808
2008 $17,715
2007 $15,617
2006 $16,208
2005 $18,605
Bristol-Myers Squibb Quarterly Revenue
(Millions of US $)
Q2 2018 $5,704
Q1 2018 $5,193
Q4 2017 $5,449
Q3 2017 $5,254
Q2 2017 $5,144
Q1 2017 $4,929
Q4 2016 $5,243
Q3 2016 $4,922
Q2 2016 $4,871
Q1 2016 $4,391
Q4 2015 $4,287
Q3 2015 $4,069
Q2 2015 $4,163
Q1 2015 $4,041
Q4 2014 $4,258
Q3 2014 $3,921
Q2 2014 $3,889
Q1 2014 $3,811
Q4 2013 $4,441
Q3 2013 $4,065
Q2 2013 $4,048
Q1 2013 $3,831
Q4 2012 $4,191
Q3 2012 $3,736
Q2 2012 $4,443
Q1 2012 $5,251
Q4 2011 $5,454
Q3 2011 $5,345
Q2 2011 $5,434
Q1 2011 $5,011
Q4 2010 $5,111
Q3 2010 $4,798
Q2 2010 $4,768
Q1 2010 $4,807
Q4 2009 $5,033
Q3 2009 $4,788
Q2 2009 $4,665
Q1 2009 $4,322
Q4 2008 $2,367
Q3 2008 $5,254
Q2 2008 $5,203
Q1 2008 $4,891
Q4 2007 $2,228
Q3 2007 $4,601
Q2 2007 $4,471
Q1 2007 $4,317
Q4 2006 $2,507
Q3 2006 $4,154
Q2 2006 $4,871
Q1 2006 $4,676
Q4 2005 $4,417
Q3 2005 $4,767
Q2 2005 $4,889
Q1 2005 $4,532
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $99.527B $20.776B
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $360.770B 17.24
Pfizer (PFE) United States $250.556B 14.67
Novartis AG (NVS) Switzerland $192.442B 16.51
Merck (MRK) United States $186.199B 16.44
AbbVie (ABBV) United States $149.625B 14.62
Novo Nordisk (NVO) Denmark $115.970B 18.54
Eli Lilly (LLY) United States $113.359B 20.98
Sanofi (SNY) France $105.440B 13.35
GlaxoSmithKline (GSK) United Kingdom $102.297B 13.66
AstraZeneca (AZN) United Kingdom $96.554B 10.62